Related Experiment Video
Updated: May 23, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic options for atrial fibrillation in 2012
Jennifer Rude1, Karla Quevedo, Lissette Rodriguez de Armas
1Texas Tech University Health Sciences Center, El Paso, USA.
Cardiovascular & Hematological Disorders Drug Targets
|April 25, 2012
Summary
Atrial fibrillation (AF) management requires preventing stroke. Newer antithrombotic drugs like dabigatran, rivaroxaban, and apixaban offer safer, effective alternatives to warfarin, eliminating the need for regular monitoring.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a prevalent arrhythmia requiring thromboembolism and stroke prevention.
- Coumarin anticoagulants, like warfarin, were the primary oral agents for decades but necessitate regular International Normalized Ratio (INR) monitoring due to variable efficacy and a narrow therapeutic window.
Purpose of the Study:
- To review newer oral antithrombotic agents (dabigatran, rivaroxaban, apixaban).
- To discuss the clinical utility and role of these novel agents in managing patients with atrial fibrillation.
Main Methods:
- Literature review of newer oral antithrombotic agents.
- Analysis of their mechanisms of action, efficacy, safety, and monitoring requirements.
Main Results:
- Newer agents (dabigatran, rivaroxaban, apixaban) offer effective anticoagulation for AF.
- These drugs provide a more predictable anticoagulant response, reducing the need for routine monitoring compared to warfarin.
Conclusions:
- Novel oral antithrombotic agents represent significant advancements in AF management.
- They provide safer and more convenient therapeutic options for stroke prevention in patients with atrial fibrillation.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...